1.Lortet-Tieulent J, Ferlay J, Bray F, Jemal A: International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. J Natl Cancer Inst 2018, 110(4):354–361.
2.Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E: Endometrial cancer. The Lancet 2016, 387(10023):1094–1108.
3.Waqar S, Khan SA, Sarfraz T, Waqar S: Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER–2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor. Pak J Med Sci 2018, 34(2):266–271.
4.Talhouk A, McAlpine JN: New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 2016, 3:14.
5.Society AC: Facts & Figures 2019. In. Atlanta, GA: American Cancer Society 2019.
6.Jiang X, Tang H, Chen T: Epidemiology of gynecologic cancers in China. J Gynecol Oncol 2018, 29(1):e7.
7.Henley SJ: Uterine Cancer Incidence and Mortality—United States, 1999–2016. MMWR Morbidity and Mortality Weekly Report 2018.
8.Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D et al: SEER Cancer Statistics Review, 1975–2016. In. Bethesda, MD: National Cancer Institute 2019.
9.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J: Cancer statistics in China, 2015. CA Cancer J Clin 2016, 66(2):115–132.
10.Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, Ilancheran A, Lee KM, Lim SE, Chia Y-N et al: Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology; London 2009. 10(11):1119–1127.
11.Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15(1):10–17.
12.Murali R, Soslow RA, Weigelt B: Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014, 15(7):e268–278.
13.Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, Zhao Y, Sun J: Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology 2015, 13(1).
14.Buza N, Roque DM, Santin AD: HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Arch Pathol Lab Med 2014, 138(3):343–350.
15.Lee YC, Lheureux S, Oza AM: Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol 2017, 29(1):47–58.
16.Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A: Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010(12):CD007926.
17.Shen F, Gao Y, Ding J, Chen Q: Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget 2017, 8(1):506–511.
18.Yang S, Thiel KW, Leslie KK: Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011, 22(4):145–152.
19.Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, Lesnick TG, Podratz KC: HER–2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res 2005, 25(4):2921–2927.
20.Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, Kumar NS, Dai DD: The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int 2013, 2013:479541.
21.Dumesic DA, Lobo RA: Cancer risk and PCOS. Steroids 2013, 78(8):782–785.
22.J. Diver E, Foster R, Rueda BR, Growdon WB: The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. The Oncologist 2015, 20(9):1058–1068.
23.Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Khunnarong J, Tanvanich S, Katanyu K, Thavaramara T, Pataradool K: Endometrial cancer in Thai women: clinico-pathological presentation and survival. Asian Pac J Cancer Prev 2010, 11(5):1267–1272.
24.Carlson M, Thiel K, Leslie K: Past, present, and future of hormonal therapy in recurrent endometrial cancer. International Journal of Women’s Health 2014:429.
25.Lee WL, Yen MS, Chao KC, Yuan CC, Ng HT, Chao HT, Lee FK, Wang PH: Hormone therapy for patients with advanced or recurrent endometrial cancer. J Chin Med Assoc 2014, 77(5):221–226.
26.Jeon Y-T, Park I-A, Kim Y-B, Kim JW, Park N-H, Kang S-B, Lee H-P, Song Y-S: Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Letters 2006, 239(2):198–204.
27.Kleine W, Maier T, Geyer H, Pfleiderer A: Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990, 38(1):59–65.
28.Tomica D, Ramic S, Danolic D, Susnjar L, Peric-Balja M, Puljiz M: Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. J Obstet Gynaecol 2018, 38(1):96–102.
29.Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I, Shalev E: Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagnostic Pathology 2014, 9(1):77.
30.Bendifallah S, Canlorbe G, Collinet P, Arsene E, Huguet F, Coutant C, Hudry D, Graesslin O, Raimond E, Touboul C et al: Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br J Cancer 2015, 112(5):793–801.
31.Maniketh I, Ravikumar G, Crasta JA, Prabhu R, Vallikad E: Estrogen and Progesterone Receptor Expression in Endometrioid Endometrial Carcinomas: A Clinicopathological Study Middle East Journal of Cancer 2014, 5(2):67–73.
32.Wang D-P, Konishi I, Koshiyama M, Mandai M, Nabu Y, Ishikawa Y, Mori T, Fuji S: Expression of c‐erbb‐2 protein and epidermal growth factor receptor in endometrial carcinomas correlation with clinicopathologic and sex steroid receptor status. Cancer 1993. 72(9):2628–2637.
33.Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P: HER–2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2010, 56(2):269–273.
34.Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O’Brien T et al: Overexpression of HER–2/neu in uterine serous papillary cancer. Clin Cancer Res 2002, 8(5):1271–1279.
35.Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T: Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 2012, 103(5):926–932.
36.Backe J, Gassel AM, Krebs S, Muller T, Caffier H: Immunohistochemically detected HER–2/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 1997, 259(4):189–195.
37.Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW: Mutations and amplification of oncogenes in endometrial cancer. Oncology 1999, 56(1):59–65.
38.Samsonova EA, Maksimova NA, Urmancheeva AF, Pozharisskii KM: [Expression of estrogen and progesterone receptors and oncoprotein HER–2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)]. Vopr Onkol 2004, 50(2):196–201.